Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Double-blind, Randomized, Three-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants

NCT02510560 is registered in ClinicalTrials.gov with Elgan Pharma Ltd. as lead sponsor.

NCT NCT02510560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02510560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Double-blind, Randomized, Three-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants
Lead sponsor
Elgan Pharma Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
October 9, 2016
Completion date
April 25, 2018
Enrollment
300 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

intestinal malabsorption, premature birth of newborn